2026 年 90 巻 1 号 p. 144-
We thank Dr. Iwaya and colleagues for their thoughtful letter regarding our study described in “Predictors of stent underexpansion for severely calcified lesions after debulking.”1
Previous studies2,3 have primarily focused on the severity and morphological characteristics of calcified lesions in the context of percutaneous coronary intervention, but, as we found,1 ≈45% of severely calcified lesions also contain lipid-rich components and the borderline between the calcified and lipid-rich areas plays a critical role in stent underexpansion (SUE), which is associated with worse clinical outcomes.2,4 This finding underscores the importance of careful assessment of lipid-rich tissue, particularly after optimal debulking of severely calcified lesions. As Dr. Iwaya et al. noted, intensive lipid-lowering therapy is crucial in managing lesions that include both calcified and lipid-rich plaque.
To minimize the risk of SUE in severely calcified lesions, initial lesion modification using modalities such as rotational atherectomy, orbital atherectomy, or intravascular lithotripsy is essential.5 After optimal debulking of the calcified lesions, if the lesion consists predominantly of calcified plaque, stent implantation is generally appropriate. However, for lesions with both calcified and lipid-rich components, a stent-free strategy combined with aggressive lipid-lowering therapy may offer advantages. Further large-scale clinical studies are needed to validate this proposed treatment approach.